Have a feature idea you'd love to see implemented?
Let us know!
BDTX Black Diamond Therapeutics Inc
Price (delayed)
$2.25
Market cap
$127.32M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.33
Enterprise value
$122.74M
Black Diamond Therapeutics is a precision oncology medicine company pioneering the discovery of small molecule, tumor-agnostic therapies. Black Diamond targets undrugged mutations in patients with genetically defined cancers. Black Diamond
Highlights
Black Diamond Therapeutics's EPS has increased by 38% YoY and by 11% QoQ
The debt has declined by 14% year-on-year and by 4.2% since the previous quarter
The quick ratio has contracted by 43% YoY and by 19% from the previous quarter
The company's equity fell by 27% YoY and by 12% QoQ
Key stats
What are the main financial stats of BDTX
Market
Valuations
Earnings
Shares outstanding
56.59M
Market cap
$127.32M
Enterprise value
$122.74M
Price to earnings (P/E)
N/A
Price to book (P/B)
1.3
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Net income
-$73.1M
EBIT
-$73.1M
EBITDA
-$72.76M
Free cash flow
-$61.12M
Per share
Balance sheet
Liquidity
EPS
-$1.33
EPS diluted
-$1.33
Free cash flow per share
-$1.08
Book value per share
$1.72
Revenue per share
$0
TBVPS
$2.44
Total assets
$137.9M
Total liabilities
$40.47M
Debt
$19.67M
Equity
$97.43M
Working capital
$94.74M
Debt to equity
0.2
Current ratio
5.55
Quick ratio
5.46
Net debt/EBITDA
0.06
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-49.6%
Return on equity
-68.1%
Return on invested capital
-64.1%
Return on capital employed
-62.4%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
BDTX stock price
How has the Black Diamond Therapeutics stock price performed over time
Intraday
-2.6%
1 week
6.13%
1 month
-12.11%
1 year
-24.5%
YTD
5.14%
QTD
5.14%
Financial performance
How have Black Diamond Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$81.36M
Net income
-$73.1M
Gross margin
N/A
Net margin
N/A
The net income has grown by 13% YoY and by 9% from the previous quarter
BDTX's operating income is up by 7% YoY and by 7% QoQ
Growth
What is Black Diamond Therapeutics's growth rate over time
Valuation
What is Black Diamond Therapeutics stock price valuation
P/E
N/A
P/B
1.3
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Black Diamond Therapeutics's EPS has increased by 38% YoY and by 11% QoQ
The P/B is 41% lower than the last 4 quarters average of 2.2 and 32% lower than the 5-year quarterly average of 1.9
The company's equity fell by 27% YoY and by 12% QoQ
Efficiency
How efficient is Black Diamond Therapeutics business performance
BDTX's return on invested capital is up by 15% year-on-year and by 8% since the previous quarter
The ROA rose by 14% YoY and by 4.1% QoQ
Black Diamond Therapeutics's ROE has increased by 13% YoY
Dividends
What is BDTX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for BDTX.
Financial health
How did Black Diamond Therapeutics financials performed over time
BDTX's current ratio is down by 43% year-on-year and by 19% since the previous quarter
The quick ratio has contracted by 43% YoY and by 19% from the previous quarter
The debt is 80% smaller than the equity
The company's equity fell by 27% YoY and by 12% QoQ
Black Diamond Therapeutics's debt to equity has increased by 18% YoY and by 11% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.